SCHEMBL2340437

SCHEMBL2340437

CCOC(=O)Cc1ccc(Cl)c(Oc2cc(Cl)cc(Br)c2)c1F

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.37
MEP1B Q16820 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
ALDH1A1 P00352 2/20 0.34
HTT P42858 2/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
THRB P10828 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
KDM4E B2RXH2 1/20 0.33
MAPT P10636 3/20 0.33
GPR35 Q9HC97 1/20 0.33
TP53 P04637 1/20 0.32
CYP4F2 P78329 1/20 0.32
CYP4A11 Q02928 1/20 0.32
POLB P06746 1/20 0.32
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4370301 0.94 MEP1B (0.37) CYP3A4MEP1BCYP2C9CYP2C19ALDH1A1
SCHEMBL2342519 0.89 CYP3A4 (0.34) CYP3A4ALDH1A1MEN1KMT2AKDM4E
SCHEMBL13492096 0.88 CYP3A4 (0.33) CYP3A4MEP1BCYP2C9CYP2C19ALDH1A1
SCHEMBL1343942 0.87 CYP3A4 (0.47) CYP3A4MEP1BCYP2C9CYP2C19GPR35
SCHEMBL2340956 0.86 MEN1 (0.37) ALDH1A1MEN1KMT2AL3MBTL1KDM4E
SCHEMBL4754754 0.85 CAMK2A (0.41) CYP3A4MEP1BCYP2C9CYP2C19THRB
SCHEMBL13481896 0.85 CYP3A4 (0.42) CYP3A4MEP1BCYP2C9CYP2C19
SCHEMBL13983342 0.84 CYP3A4 (0.53) CYP3A4CYP2C9CYP2C19ALDH1A1HTT
SCHEMBL4752685 0.81 MEP1B (0.38) CYP3A4MEP1BCYP2C9CYP2C19ALDH1A1
SCHEMBL1342509 0.80 CYP3A4 (0.51) CYP3A4CYP2C9CYP2C19GPR35TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293778-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-10-23 US disclosed
EP-1773790-B1 BENZYLTRIAZOLONE COMPOUNDS AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS HOFFMANN LA ROCHE (CH) 2012-08-15 EP disclosed
US-20110207688-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS DUNN JAMES PATRICK 2011-08-25 US disclosed
US-7666891-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2010-02-23 US disclosed
US-7625897-B2 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC (US) 2009-12-01 US disclosed
US-7625897-B2 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC (US) 2009-12-01 US disclosed
US-7625897-B2 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC (US) 2009-12-01 US disclosed
EP-1937651-B1 NNRT INHIBITORS HOFFMANN LA ROCHE (CH) 2008-12-24 EP disclosed
WO-2008157273-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-24 WO disclosed
WO-2008157330-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-24 WO disclosed
EP-1937651-A1 NNRT INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2008-07-02 EP disclosed
EP-1773790-A1 BENZYLTRIAZOLONE COMPOUNDS AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2007-04-18 EP disclosed
WO-2007039463-A1 NNRT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-04-12 WO disclosed
US-20070078128-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2007-04-05 US disclosed
US-20070078128-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2007-04-05 US disclosed
US-20070078128-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2007-04-05 US disclosed
US-20060025462-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2006-02-02 US disclosed
WO-2006010545-A1 BENZYLTRIAZOLONE COMPOUNDS AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2006-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078128-A1 Non-nucleoside reverse transcriptase inhibitors SAMHD1, HPRT1, RTF1 CYP3A4 350/4885MEP1B 2164/4885CYP2C9 1239/4885
US-20110207688-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS MAVS, IRF3, ZC3HAV1 CYP3A4 114/4885MEP1B 1403/4885CYP2C9 942/4885
US-20060025462-A1 Heterocyclic antiviral compounds MAVS, IRF3, ZC3HAV1 CYP3A4 893/4885MEP1B 433/4885CYP2C9 1216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.